Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

L19-IL2 Monoclonal Antibody-Cytokine Fusion Protein

Known as: L19-IL2 
An immunoconjugate consisting of the recombinant form of the cytokine interleukin-2 (IL-2) fused to a human single-chain Fv (scFv) antibody fragment… Expand
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study
Abstract The intratumoral injection of cytokines, in particular IL2, has shown promise for cutaneous melanoma patients with… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Highly Cited
2014
Highly Cited
2014
Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects
Purpose: Radiotherapy modifies the tumor microenvironment and causes the release of tumor antigens, which can enhance the effect… Expand
  • figure 1
  • figure 2
  • figure 3
Highly Cited
2014
Highly Cited
2014
Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses
Weide and colleagues show that intralesional therapy using the immunocytokine L19–IL2 elicited a high rate of clinical and… Expand
  • table 1
  • table 2
  • figure 2
  • figure 2
  • table 3
Highly Cited
2013
Highly Cited
2013
The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF.
Systemic high-dose IL2 promotes long-term survival in a subset of metastatic melanoma patients, but this treatment is accompanied… Expand
Highly Cited
2012
Highly Cited
2012
Local delivery of IL-2 reduces atherosclerosis via expansion of regulatory T cells.
OBJECTIVE Recent studies indicate that regulatory T cells (Tregs) attenuate murine atherosclerosis. Since interleukin (IL)-2… Expand
  • figure 3
Highly Cited
2011
Highly Cited
2011
A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma
Purpose: L19-IL2 is an immunocytokine composed of an antibody fragment specific to the EDB domain of fibronectin, a tumor… Expand
  • table 1
  • table 2
Highly Cited
2010
Highly Cited
2010
The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma.
BACKGROUND L19-IL2, a tumour-targeting immunocytokine composed of the recombinant human antibody fragment L19 (specific to the… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
2010
2010
Therapy‐induced antitumor vaccination in neuroblastomas by the combined targeting of IL‐2 and TNFα
L19‐IL2 and L19TNFα are fusion proteins composed of L19(scFv), specific for the angiogenesis‐associated ED‐B containing… Expand
Highly Cited
2009
Highly Cited
2009
Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2.
The antibody-mediated delivery of therapeutic agents to sites of angiogenesis is an attractive strategy for anticancer therapy… Expand
  • table 1
Highly Cited
2008
Highly Cited
2008
The Targeted Immunocytokine L19-IL2 Efficiently Inhibits the Growth of Orthotopic Pancreatic Cancer
Purpose: Effective control of pancreatic cancer has been hampered primarily by the lack of tumor specificity of current treatment… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE